Loading...
•
Jun 30, 2024
Puma Biotechnology Q2 2024 Earnings Report
Puma Biotechnology's financial performance declined in Q2 2024, with revenue and net income decreasing compared to the same period last year.
Key Takeaways
Puma Biotechnology reported a decrease in total revenue to $47.1 million and a net loss of $4.5 million for the second quarter of 2024. The decline in revenue was primarily driven by lower product revenue from NERLYNX. The company is focusing on the development of alisertib and anticipates key milestones in the next 12 months.
Total revenue for Q2 2024 was $47.1 million, a decrease from $54.6 million in Q2 2023.
Net loss for Q2 2024 was $4.5 million, compared to net income of $2.1 million in Q2 2023.
Net product revenue from NERLYNX was $44.4 million in Q2 2024, down from $51.6 million in Q2 2023.
The company anticipates key milestones over the next 12 months, including the initiation of ALISCA™-Breast1 and interim data from ALISCA™-Lung1.
Revenue by Segment
Forward Guidance
Puma Biotechnology provided financial outlook for the third quarter and full year 2024.
Positive Outlook
- Net product revenue for Q3 2024 is expected to be $50 - $53 million.
- Royalty revenue for Q3 2024 is expected to be $20 - $22 million.
- Net income for Q3 2024 is expected to be $11 - $13 million.
- Net product revenue for full year 2024 is expected to be $183 - $190 million.
- Net income for full year 2024 is expected to be $12 - $15 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...